|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
2/28/2013
|
MAIN ALAN J
|
EVP, Pharmaceutical Research
|
-12,572
|
$1.98
|
-9.87%
|
|
2/28/2013
|
Lapuerta Pablo
|
EVP, Clin Dev and CMO
|
-4,725
|
$1.98
|
-36.35%
|
|
2/28/2013
|
SANDS ARTHUR T
|
President & CEO
|
-20,034
|
$1.98
|
-2.08%
|
|
2/28/2013
|
Tessmer James F
|
VP, Finance & Accounting
|
-3,807
|
$1.98
|
-7.35%
|
|
2/28/2013
|
WADE JEFFREY L
|
EVP, Corp Dev and CFO
|
-10,461
|
$1.98
|
-8.62%
|
|
2/28/2013
|
ZAMBROWICZ BRIAN P
|
EVP, Chief Scientific Officer
|
-11,692
|
$1.98
|
-4.76%
|
|
1/31/2013
|
MAIN ALAN J
|
EVP, Pharmaceutical Research
|
-12,537
|
$2.11
|
-11.81%
|
|
1/31/2013
|
Tessmer James F
|
VP, Finance & Accounting
|
-4,310
|
$2.11
|
-10.29%
|
|
1/31/2013
|
ZAMBROWICZ BRIAN P
|
EVP, Chief Scientific Officer
|
-13,499
|
$2.11
|
-6.23%
|
|
1/31/2013
|
SANDS ARTHUR T
|
President & CEO
|
-21,434
|
$2.11
|
-2.35%
|
|
1/31/2013
|
WADE JEFFREY L
|
EVP, Corp Dev and CFO
|
-10,317
|
$2.11
|
-11.05%
|
|
10/23/2012
|
Invus, CV
|
Senior Executive Officer
|
3,000,000
|
$2.25
|
1.07%
|
|
10/23/2012
|
Artal International S.C.A.
|
Senior Executive Officer
|
3,000,000
|
$2.25
|
1.07%
|
|
2/28/2012
|
SANDS ARTHUR T
|
President & CEO
|
-9,588
|
$1.78
|
-1.13%
|
|
2/28/2012
|
ZAMBROWICZ BRIAN P
|
EVP, Chief Scientific Officer
|
-5,621
|
$1.78
|
-3.12%
|
|
2/28/2012
|
WADE JEFFREY L
|
EVP, Corp Dev and CFO
|
-4,959
|
$1.78
|
-7.43%
|
|
2/28/2012
|
MAIN ALAN J
|
EVP, Pharmaceutical Research
|
-5,907
|
$1.78
|
-9.20%
|
|
2/28/2012
|
Tessmer James F
|
VP, Finance & Accounting
|
-2,299
|
$1.78
|
-7.42%
|
|
12/22/2011
|
Ulys, LLC
|
Senior Executive Officer
|
113,382,063
|
$1.13
|
82.77%
|
|
12/22/2011
|
Ulys, LLC
|
Senior Executive Officer
|
1,622,184
|
$1.13
|
41.27%
|
|
12/22/2011
|
MAIN ALAN J
|
EVP, Pharmaceutical Research
|
19,211
|
$1.13
|
42.72%
|
|
12/22/2011
|
BARKER SAM L
|
Director
|
34,000
|
$1.13
|
51.52%
|
|
12/22/2011
|
SANDS ARTHUR T
|
President & CEO
|
25,000
|
$1.13
|
3.18%
|
|
2/23/2011
|
MAIN ALAN J
|
EVP, Pharmaceutical Research
|
-5,926
|
$1.81
|
-11.64%
|
|
2/23/2011
|
Tessmer James F
|
VP, Finance & Accounting
|
-2,116
|
$1.81
|
-8.27%
|
|
2/23/2011
|
SANDS ARTHUR T
|
President & CEO
|
-10,464
|
$1.81
|
-1.31%
|
|
2/23/2011
|
WADE JEFFREY L
|
EVP, Corp Dev and CFO
|
-5,926
|
$1.81
|
-10.99%
|
|
2/23/2011
|
ZAMBROWICZ BRIAN P
|
EVP, Chief Scientific Officer
|
-7,881
|
$1.81
|
-4.73%
|